Stock Scorecard
Stock Summary for Precision Biosciences Inc (DTIL) - $5.67 as of 10/6/2025 10:10:16 PM EST
Total Score
9 out of 30
Safety Score
28 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for DTIL
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for DTIL
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for DTIL
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for DTIL
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for DTIL (28 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Financial Details for DTIL
Company Overview |
|
|---|---|
| Ticker | DTIL |
| Company Name | Precision Biosciences Inc |
| Country | USA |
| Description | Precision BioSciences, Inc. (Ticker: DTIL) is a leading genome editing company specializing in the development of innovative therapeutic products to address a wide range of diseases. Headquartered in Durham, North Carolina, Precision BioSciences leverages its proprietary ARCUS platform to create precise and targeted genetic therapies, with a strong focus on oncology, genetic disorders, and infectious diseases. The company's robust pipeline and commitment to advancing genetic medicine position it as a significant player in the biopharmaceutical industry, catering to the evolving needs of patients and healthcare providers alike. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 5.67 |
| Price 4 Years Ago | 222.00 |
| Last Day Price Updated | 10/6/2025 10:10:16 PM EST |
| Last Day Volume | 143,045 |
| Average Daily Volume | 88,934 |
| 52-Week High | 9.39 |
| 52-Week Low | 3.61 |
| Last Price to 52 Week Low | 57.06% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.22 |
| Sector PE | 41.70 |
| 5-Year Average PE | -82.62 |
| Free Cash Flow Ratio | 1.07 |
| Industry Free Cash Flow Ratio | 14.45 |
| Sector Free Cash Flow Ratio | 30.25 |
| Current Ratio Most Recent Quarter | 5.18 |
| Total Cash Per Share | 5.28 |
| Book Value Per Share Most Recent Quarter | 2.93 |
| Price to Book Ratio | 1.88 |
| Industry Price to Book Ratio | 29.58 |
| Sector Price to Book Ratio | 32.02 |
| Price to Sales Ratio Twelve Trailing Months | 50.85 |
| Industry Price to Sales Ratio Twelve Trailing Months | 44.16 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.22 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 11,787,000 |
| Market Capitalization | 66,832,290 |
| Institutional Ownership | 44.22% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 111.69% |
| Reported EPS 12 Trailing Months | -10.15 |
| Reported EPS Past Year | -4.34 |
| Reported EPS Prior Year | -0.07 |
| Net Income Twelve Trailing Months | -78,255,000 |
| Net Income Past Year | 7,167,000 |
| Net Income Prior Year | -61,319,000 |
| Quarterly Revenue Growth YOY | -100.00% |
| 5-Year Revenue Growth | 25.30% |
| Operating Margin Twelve Trailing Months | -121,539.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 62,242,000 |
| Total Cash Past Year | 85,899,000 |
| Total Cash Prior Year | 116,678,000 |
| Net Cash Position Most Recent Quarter | 39,888,000 |
| Net Cash Position Past Year | 63,578,000 |
| Long Term Debt Past Year | 22,321,000 |
| Long Term Debt Prior Year | 22,223,000 |
| Total Debt Most Recent Quarter | 22,354,000 |
| Equity to Debt Ratio Past Year | 0.72 |
| Equity to Debt Ratio Most Recent Quarter | 0.60 |
| Total Stockholder Equity Past Year | 56,393,000 |
| Total Stockholder Equity Prior Year | 18,861,000 |
| Total Stockholder Equity Most Recent Quarter | 34,054,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -64,120,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -5.44 |
| Free Cash Flow Past Year | -58,695,000 |
| Free Cash Flow Prior Year | -86,392,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.15 |
| MACD Signal | 0.08 |
| 20-Day Bollinger Lower Band | 4.11 |
| 20-Day Bollinger Middle Band | 4.85 |
| 20-Day Bollinger Upper Band | 5.60 |
| Beta | 1.71 |
| RSI | 63.75 |
| 50-Day SMA | 13.44 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 31.66 |
System |
|
| Modified | 10/6/2025 10:11:03 PM EST |